ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1672

The Impact of Systemic Sclerosis (SSc) on Women’s Health Evaluated with a New SSc-specific Patient-reported Questionnaire

Maria Grazia Lazzaroni1, Liala Moschetti1, Eleonora Pedretti1, Andrea Lojacono2, Francesca Ramazzotto3, Cristina Zanardini3, Zatti Sonia3, Angela Tincani4, Franco Franceschini1, Paolo Airò5 and Laura Andreoli1, 1Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, 2Obstetrics and Gynecology, ASST Garda, Desenzano del Garda, Brescia, Brescia, Italy, 3Obstetrics and Gynecology, ASST Spedali Civili and University of Brescia, Brescia, Italy, 4Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Gussago, Italy, 5Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy

Meeting: ACR Convergence 2022

Keywords: gender, pregnancy, Sexual Function, Systemic sclerosis, Women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Abstracts: Reproductive Issues in Rheumatic Disorders

Session Type: Abstract Session

Session Time: 10:30AM-11:30AM

Background/Purpose: Systemic Sclerosis (SSc) has a strong female predominance and can significantly impair the everyday quality of life of patients. We aimed at designing a SSc-specific, patient-reported questionnaire to explore the aspects of women’s health most affected by the disease and additionally evaluate their association with clinical features.

Methods: The questionnaire was created together with Obstetricians-Gynecologists (70 questions, 5 sections) and administered to consecutive patients with SSc (2013 ACR/EULAR classification criteria) regularly attending our Clinic during 2021. The Female Sexual Function Index (FSFI) questionnaire was also administered. Data regarding clinical and laboratory features were obtained from clinical charts.

Results: The questionnaires were proposed to 114 patients; among 100 who accepted to participate (median age: 59 [43-67] years, median disease duration: 11 [6-17] years; limited cutaneous subset in 75%; anti-centromere positivity in 44%), 48 had received SSc diagnosis during reproductive age (< 45 years).

A regular gynecological follow-up was not declared by 40% of the women. These patients, as compared to those regularly attending gynecological controls, were older at diagnosis and at questionnaire (Tab 1), had lower school education (p:0.02) and were more frequently post-menopausal (p:0.01). Clinically, they presented a more severe SSc phenotype requiring more systemic therapies (Tab 1).

Regarding sexuality, 59% reported that it was negatively affected by SSc, especially by vaginal dryness (67%), digital ulcers (37%), gastro-intestinal involvement (37%) and dyspnea (20%). Among 39 patients who completed FSFI, 67% had sexual dysfunction (Tab 1).

Considering 48 patients with SSc-diagnosis during reproductive age: 73% never discussed contraceptive methods with their SSc-Clinicians; 54% desired a pregnancy after diagnosis, but 30% did not satisfy their family plan (Tab 1). In addition, half of them reported they did not know whether a SSc woman could experience disease worsening or take safe medications during pregnancy, and have children also affected by SSc (Fig 1).

After SSc onset, 22 women declared 43 pregnancies with 33 live births. A higher frequency of cesarean sections (p:0.01) and a lower weight at birth of the babies (p:0.01), as compared to 146 pregnancies (121 live births) occurred before SSc onset, were reported. An improvement or stability of SSc-manifestations during pregnancy was reported by 77% of the patients.

Conclusion: The newly created specific questionnaire was instrumental to facilitate physician-patient communication about ‘women’s health’ and highlighted the aspects most affected by SSc and the unmet needs of the patients. The analysis of the clinical features confirmed that a greater disease severity can have a major impact on the quality of life of these women.

GILS (Gruppo Italiano Lotta Sclerodermia) is kindly acknowledged for supporting the study with a grant.

Supporting image 1

Table 1. Clinical features of the patients at the questionnaire.
Continuous variables are reported as median (IQR) and compared with Mann-Whitney test; categorical variables are reported as number/number of available data (%) and compared with Chi Squared/Exact Fisher test. *p<0.05, comparison with patients who had regular gynecological follow-up; ^p<0.05, comparison with patients who satisfied the desired family size after SSc diagnosis; °p<0.05, comparison with patients with FSFI >26.55.

Supporting image 2

Figure 1. Results of the section of the questionnaire regarding patients’ knowledge about pregnancy issues.


Disclosures: M. Lazzaroni, None; L. Moschetti, None; E. Pedretti, None; A. Lojacono, None; F. Ramazzotto, None; C. Zanardini, None; Z. Sonia, None; A. Tincani, GlaxoSmithKlein(GSK), UCB; F. Franceschini, None; P. Airò, Bristol-Myers-Squibb, Boehringer Ingelheim, Roche, Jannsen, CSL Behring; L. Andreoli, GlaxoSmithKlein(GSK), Janssen, Novartis, UCB, Werfen.

To cite this abstract in AMA style:

Lazzaroni M, Moschetti L, Pedretti E, Lojacono A, Ramazzotto F, Zanardini C, Sonia Z, Tincani A, Franceschini F, Airò P, Andreoli L. The Impact of Systemic Sclerosis (SSc) on Women’s Health Evaluated with a New SSc-specific Patient-reported Questionnaire [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-impact-of-systemic-sclerosis-ssc-on-womens-health-evaluated-with-a-new-ssc-specific-patient-reported-questionnaire/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-systemic-sclerosis-ssc-on-womens-health-evaluated-with-a-new-ssc-specific-patient-reported-questionnaire/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology